<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1662-4548</issn><issn pub-type="epub">1662-453X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5635042</article-id><article-id pub-id-type="doi">10.3389/fnins.2017.00553</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Mitochondrial Bioenergetics Is Altered in Fibroblasts from Patients with Sporadic Alzheimer's Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>P&#x000e9;rez</surname><given-names>Mar&#x000ed;a J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ponce</surname><given-names>Daniela P.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/479139/overview"/></contrib><contrib contrib-type="author"><name><surname>Osorio-Fuentealba</surname><given-names>Cesar</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/398757/overview"/></contrib><contrib contrib-type="author"><name><surname>Behrens</surname><given-names>Maria I.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Quintanilla</surname><given-names>Rodrigo A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/63716/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Laboratory of Neurodegenerative Diseases, Universidad Aut&#x000f3;noma de Chile</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><aff id="aff2"><sup>2</sup><institution>Centro de Investigaci&#x000f3;n y Estudio del Consumo de Alcohol en Adolescentes</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><aff id="aff3"><sup>3</sup><institution>Instituto de Ciencias Biom&#x000e9;dicas, Universidad de Chile</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><aff id="aff4"><sup>4</sup><institution>Departamento Kinesiolog&#x000ed;a, Universidad Metropolitana de Ciencias de la Educaci&#x000f3;n</institution>, <addr-line>&#x000d1;u&#x000f1;oa</addr-line>, <country>Chile</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Umberto di Porzio, Consiglio Nazionale Delle Ricerche (CNR), Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Lezi E, Duke University, United States; Scott Edward Counts, Michigan State University, United States</p></fn><corresp id="fn001">*Correspondence: Rodrigo A. Quintanilla <email xlink:type="simple">rodrigo.quintanilla@uautonoma.cl</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>11</volume><elocation-id>553</elocation-id><history><date date-type="received"><day>12</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 P&#x000e9;rez, Ponce, Osorio-Fuentealba, Behrens and Quintanilla.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>P&#x000e9;rez, Ponce, Osorio-Fuentealba, Behrens and Quintanilla</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The identification of an early biomarker to diagnose Alzheimer's disease (AD) remains a challenge. Neuropathological studies in animal and AD patients have shown that mitochondrial dysfunction is a hallmark of the development of the disease. Current studies suggest the use of peripheral tissues, like skin fibroblasts as a possibility to detect the early pathological alterations present in the AD brain. In this context, we studied mitochondrial function properties (bioenergetics and morphology) in cultured fibroblasts obtained from AD, aged-match and young healthy patients. We observed that AD fibroblasts presented a significant reduction in mitochondrial length with important changes in the expression of proteins that control mitochondrial fusion. Moreover, AD fibroblasts showed a distinct alteration in proteolytic processing of OPA1, a master regulator of mitochondrial fusion, compared to control fibroblasts. Complementary to these changes AD fibroblasts showed a dysfunctional mitochondrial bioenergetics profile that differentiates these cells from aged-matched and young patient fibroblasts. Our findings suggest that the human skin fibroblasts obtained from AD patients could replicate mitochondrial impairment observed in the AD brain. These promising observations suggest that the analysis of mitochondrial bioenergetics could represent a promising strategy to develop new diagnostic methods in peripheral tissues of AD patients.</p></abstract><kwd-group><kwd>mitochondria</kwd><kwd>Alzheimer's disease</kwd><kwd>biomarker</kwd><kwd>OPA1</kwd><kwd>fibroblasts</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100002850</named-content></funding-source><award-id rid="cn001">1140968</award-id><award-id rid="cn001">1170441</award-id><award-id rid="cn001">1151297</award-id><award-id rid="cn001">1113024</award-id></award-group><award-group><funding-source id="cn002">Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica<named-content content-type="fundref-id">10.13039/501100002848</named-content></funding-source><award-id rid="cn002">PIA ANILLO ACT1411</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><equation-count count="0"/><ref-count count="64"/><page-count count="13"/><word-count count="7651"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>AD is one of the most common neurodegenerative diseases worldwide and is considered the leading cause of dementia in the world's adult population (Hirtz et al., <xref rid="B20" ref-type="bibr">2007</xref>). From a genetic point of view, AD can be classified into two types, familial cases with autosomal dominant inheritance (FAD), and sporadic AD which primary cause are still unknown (SAD) (Barage and Sonawane, <xref rid="B4" ref-type="bibr">2015</xref>). The accumulation of misfolded proteins such as the amyloid beta peptide (A&#x000df;) and hyperphosphorylated tau are considered essential components in the pathogenesis of AD (Querfurth and LaFerla, <xref rid="B46" ref-type="bibr">2010</xref>; Huang and Mucke, <xref rid="B23" ref-type="bibr">2012</xref>). Current evidence suggests that mitochondrial impairment is also a hallmark of AD, as mitochondrial dysfunction appears before the establishment of tau and A&#x003b2; pathology contributing to synaptic impairment observed in AD (Knott et al., <xref rid="B27" ref-type="bibr">2008</xref>; Cabezas-Opazo et al., <xref rid="B8" ref-type="bibr">2015</xref>, Yao et al., <xref rid="B62" ref-type="bibr">2011</xref>).</p><p>AD mainly affects memory and cognitive functions, and currently, there is an urgent need for an early biomarker with the reliability and accuracy to diagnose this disease. Nowadays, AD diagnosis is based on neuropsychological surveys and in the exclusion of other age-related dementias in consultant patients (Lanfranco et al., <xref rid="B28" ref-type="bibr">2012</xref>). Analysis of this data has determined three stages of AD progression: preclinical AD, mild cognitive impairment type Alzheimer's, and Alzheimer's type dementia (Lanfranco et al., <xref rid="B28" ref-type="bibr">2012</xref>). Unfortunately, the confirmation of AD is only possible during the patient's autopsy observing the characteristic pathological brain lesions (Khan and Alkon, <xref rid="B26" ref-type="bibr">2015</xref>).</p><p>Several groups had suggested the use of peripheral tissues as a reliable source of biomarkers that could reflex the metabolic changes in the brain (Yao et al., <xref rid="B62" ref-type="bibr">2011</xref>; Perez et al., <xref rid="B44" ref-type="bibr">2016</xref>). In fact, there are several examples of using skin fibroblasts to study metabolic abnormalities related to neurological (Zoumakis et al., <xref rid="B64" ref-type="bibr">2007</xref>), psychiatric (Kalman et al., <xref rid="B25" ref-type="bibr">2016</xref>), neurometabolic (Khan and Alkon, <xref rid="B26" ref-type="bibr">2015</xref>) and neurodegenerative diseases (Lopez-Erauskin et al., <xref rid="B29" ref-type="bibr">2012</xref>; Ambrosi et al., <xref rid="B2" ref-type="bibr">2014</xref>), in particular Huntington's disease (Marchina et al., <xref rid="B33" ref-type="bibr">2014</xref>), Parkinson's disease (Rakovic et al., <xref rid="B50" ref-type="bibr">2010</xref>; Cooper et al., <xref rid="B13" ref-type="bibr">2012</xref>; Papkovskaia et al., <xref rid="B43" ref-type="bibr">2012</xref>; Mcneill et al., <xref rid="B35" ref-type="bibr">2013</xref>), and genetic forms of Amyotrophic Lateral Sclerosis (Bartolome et al., <xref rid="B5" ref-type="bibr">2013</xref>; Prause et al., <xref rid="B45" ref-type="bibr">2013</xref>; Allen et al., <xref rid="B1" ref-type="bibr">2014</xref>). For that reason, it has been suggested that biochemical changes in brain cells could be reflected in peripheral tissues derived from ectoderm, such as skin (Zoumakis et al., <xref rid="B64" ref-type="bibr">2007</xref>), and that this tissue represents a suitable model to study potential new biomarkers in AD and other neurodegenerative diseases (Khan and Alkon, <xref rid="B26" ref-type="bibr">2015</xref>).</p><p>In AD brains, mitochondrial dysfunction is commonly presented as a respiratory failure, with a reduced ATP production, increased reactive oxygen species (ROS) production, abnormal calcium regulation, and mitochondrial fragmentation (Hu et al., <xref rid="B22" ref-type="bibr">2016</xref>). Interestingly, evidence in cortical samples from AD patients suggests an unbalance of mitochondrial fission and fusion, as mitochondrial dynamics is inclined toward fission (Manczak et al., <xref rid="B32" ref-type="bibr">2011</xref>). Therefore, we will evaluate mitochondrial deficits associated with neurodegeneration in fibroblasts of young, age-matched healthy and sporadic Alzheimer's disease patients.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec><title>Materials</title><p>Chemicals and culture materials were obtained from Sigma-Aldrich (St. Louis, MO, USA), Roche (Alameda, CA, USA), and Invitrogen (Carlsbad, CA, USA). Fluo-3 AM, Thapsigargin, Mitotracker Green FM (MitoGreen), Mitotracker Red CM-H2XRos (MitoRed), FCCP and 2&#x02032;,7&#x02032;-DCF were obtained from Molecular Probes (Eugene, OR, USA).</p></sec><sec><title>Patients and cell culture fibroblasts</title><p>Skin fibroblasts were obtained from 3 AD patients, three age-matched healthy controls, and one young healthy control, and cultured in growth media containing MEM&#x003b1; (Biological Industries) with 10%FBS (Gibco) and 1% penicillin-streptomycin (Corning) (Vangipuram et al., <xref rid="B56" ref-type="bibr">2013</xref>). The individuals were recruited after providing informed consent approved by the Ethics Committee of the Hospital Cl&#x000ed;nico de la Universidad de Chile, and Universidad Aut&#x000f3;noma de Chile. AD diagnosis was established according to the National Institute of Neurological and Communicative Diseases and Stroke&#x02013;AD and Related Disorders Association (Mckhann et al., <xref rid="B34" ref-type="bibr">1984</xref>) tests and the Clinical Dementia Rating (CDR) scale (Morris, <xref rid="B37" ref-type="bibr">1993</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics of the patients.</p></caption><table frame="hsides" rules="groups"><thead><tr style="border-bottom: thin solid #000000;"><th valign="top" align="left" rowspan="1" colspan="1"><bold>Patient</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Range age</bold></th><th valign="top" align="center" colspan="3" rowspan="1"><bold>Tests</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Diagnostic</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>CDR</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>MoCA</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>MMSE</bold></td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ADP1</td><td valign="top" align="center" rowspan="1" colspan="1">80&#x02013;85</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="left" rowspan="1" colspan="1">Alzheimer</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ADP2</td><td valign="top" align="center" rowspan="1" colspan="1">70&#x02013;75</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Alzheimer</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ADP3</td><td valign="top" align="center" rowspan="1" colspan="1">65&#x02013;70</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Alzheimer</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NP1</td><td valign="top" align="center" rowspan="1" colspan="1">70&#x02013;75</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">Control</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NP2</td><td valign="top" align="center" rowspan="1" colspan="1">75&#x02013;80</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">Control</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NP3</td><td valign="top" align="center" rowspan="1" colspan="1">80&#x02013;85</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">25</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">Control</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">YP</td><td valign="top" align="center" rowspan="1" colspan="1">25&#x02013;30</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Control</td></tr></tbody></table><table-wrap-foot><p><italic>The table represents the range of age and diagnosis type for each patient according to the cognitive test applied. The CDR scale indicates the severity of dementia; whereby severe dementia degree (CDR 3), mild-to-moderate dementia (CDR 2), preclinical dementia (CDR 1), and healthy donors (CDR 0). The maximum score for the Mini-mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) is 30, with lower scores associated with greater cognitive deterioration</italic>.</p></table-wrap-foot></table-wrap></sec><sec><title>Determination of mitochondrial length</title><p>Estimation of mitochondrial length was calculated measuring the length of individual mitochondria along the fibroblasts. Cells were preloaded with MitoGreen (500 nM) at 37&#x000b0;C for 30 min in Krebs-Ringer-HEPES (KRH) buffer supplemented with 5 mM glucose (Quintanilla et al., <xref rid="B49" ref-type="bibr">2009</xref>). The mitochondrial length was classified in: short (&#x0003e;5 &#x003bc;m), medium (5&#x02013;40 &#x003bc;m) and long (&#x0003c;40 &#x003bc;m) size by the method used in our previous publications (Quintanilla et al., <xref rid="B49" ref-type="bibr">2009</xref>; Hom et al., <xref rid="B21" ref-type="bibr">2011</xref>). We analyzed over 500 individual mitochondria per patient in two independents experiments. For the determination of mitochondrial length following a stimulus, cells previously loaded with MitoGreen were treated with thapsigargin 10 &#x003bc;M. Fluorescence images were taken in an epifluorescence microscopy (Leica LX6000, Germany) using a 63&#x000d7; oil objective. For each independent experiment, we analyzed mitochondrial population from 30 to 40 cells, measuring 25 images for an experiment in each patient, using Image J software.</p></sec><sec><title>Western blot analysis</title><p>Cells were lysed in RIPA lysis buffer (AMRESCO) plus protease inhibitor cocktail (Roche). 30 &#x003bc;g of total protein extracts were resolved on a SDS-electrophoresis gel and transferred to nitrocellulose membranes. After blocking process, the membranes were incubated with rabbit polyclonal anti-OPA1 (Thermo Fisher 1:1,000 dilution), rabbit polyclonal anti-DRP1 (Thermo Fisher 1:1,000) and rabbit polyclonal anti-MFN1 (Santa Cruz 1:1,000) antibodies. The equal loading and transfer of membranes were subsequently re-tested with anti-&#x003b2;-actin (Thermo Fisher 1:2,000). After treatment with HRP-linked goat anti-mouse or anti-rabbit secondary antibodies (Thermo Fisher 1:2,000) as indicated, immunoreactive proteins were detected using enhanced chemiluminescence reactive (ECL, Thermo Fisher).</p></sec><sec><title>Mitochondrial membrane potential</title><p>The mitochondrial potential was determined using the mitochondrial dye TMRM in non-quenching mode, as described previously with modifications (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>; Vargas et al., <xref rid="B57" ref-type="bibr">2014</xref>). Mitochondrial potential levels were expressed as the average of fluorescence signal (F) per area in every image minus the intensity of background fluorescence (F0). For determinations in basal conditions, fibroblasts were preloaded with TMRM (100 nM) in KRH-glucose buffer at 37&#x000b0;C for 45 min. Also, to compare mitochondrial potential following a stimulus, we treated the cells previously loaded with TMRM with thapsigargin 10 &#x003bc;M. For each independent experiment, the intensity of the signal was analyzed in more than 30 cells, measuring 25 images per experiment in each patient using Image J software.</p></sec><sec><title>Determination of ROS levels</title><p>ROS levels were evaluated using chloromethyl-2,7-dichlorodihydrofluorescein diacetate (DCF) dye (Eugene, OR). Cultured fibroblasts were incubated with 10 &#x003bc;M DCF in KRH-glucose buffer at 37&#x000b0;C for 30 min (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>). Images were taken adjusting the same exposure time and gain detector to diminish the photobleaching of the dye (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>). Quantification of fluorescence intensity for each separate experiment was carried out analyzing the intensity of the signal in 25 images for every indicated condition using Image J software. Results are express as the average of fluorescence signal per area in every picture.</p></sec><sec><title>Determination of ATP levels</title><p>Total ATP levels were measured in the fibroblasts lysate using a luciferin/luciferase bioluminescence assay kit (ATP Determination Kit #A22066, Molecular Probes, Invitrogen). The amount of ATP in each sample was calculated from standard curves and normalized to the total protein concentration.</p></sec><sec><title>Cytosolic calcium measurements</title><p>Cytoplasmic calcium changes were determined using Fluo-3 AM dye. Fibroblasts were loaded with 5 &#x003bc;M Fluo-3 AM in KRH-glucose buffer at 37&#x000b0;C for 30 min (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>). The signal of the fluorescence background was subtracted from cytosolic cell fluorescence measurements in every experiment, and cytosolic calcium levels were presented as a pseudo-ratio (&#x00394;F/F<sub>0</sub>), as previously described (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>). To evaluate basal cytosolic calcium levels, we analyzed 25 images for each experiment in every indicated condition. To determinate changes in cytosolic calcium levels following a stimulus, we treated the cells previously loaded with Fluo-3 AM, or in the presence of the mitochondrial uncoupler FCCP (10 &#x003bc;M), or thapsigargin (10 &#x003bc;M), and the changes in fluorescence intensity were registered from 15 cells on average per experiment. Fluorescence intensity and quantification were made using Image J software (NIH).</p></sec><sec><title>Statistical analysis</title><p>Student &#x0201c;<italic>t</italic>&#x0201d; test analyzed statistical differences between two group of data. For multiple comparisons, one-way ANOVA was used, followed by Tukey test <italic>a posteriori</italic>. Differences were considered significant if <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.01, or <italic>p</italic> &#x0003c; 0.001 as indicated.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Determination of mitochondrial length in AD fibroblasts</title><p>To study changes in mitochondrial morphology of sporadic AD fibroblasts, we measured mitochondrial length using MitoGreen in all conditions (Figures <xref ref-type="fig" rid="F1">1A&#x02013;C</xref>). AD fibroblasts presented a reduction of 30% in mitochondrial length compared to control patients (Figure <xref ref-type="fig" rid="F1">1B</xref>). Further classification of the mitochondrial population (see Methods) indicated that AD patients presented 20% more of shorter mitochondria than control patients, with a significant decrease in medium and long size mitochondria compared to control cells (Figure <xref ref-type="fig" rid="F1">1C</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>AD cultured fibroblasts present a decrease in mitochondrial length. <bold>(A)</bold> Cells were loaded with MitoGreen to determinate mitochondrial morphology. Bar = 10 &#x003bc;m. <bold>(B)</bold> Quantification of the mitochondrial length average obtained from microscopy analysis (see Methods). Data are mean &#x000b1; <italic>SE, n</italic> = 3 (technical replicates for each subject). <sup>*</sup><italic>p</italic> &#x0003c; 0.001 indicate differences between groups calculated by Student <italic>t</italic>-test. <bold>(C)</bold> Distribution of mitochondrial length in cultured fibroblasts from AD and control patients. Mitochondrial lengths were grouped in short, medium and long size. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <sup>*</sup><italic>p</italic> &#x0003c; 0.005, <sup>**</sup><italic>p</italic> &#x0003c; 0.003 indicates differences between groups calculated by Student <italic>t</italic>-test between short, medium and long mitochondria from AD and control patients.</p></caption><graphic xlink:href="fnins-11-00553-g0001"/></fig></sec><sec><title>Mitochondrial dynamics is altered in AD fibroblasts</title><p>Mitochondrial morphology is modulated by specific large GTPases proteins that control both mitochondrial fission and fusion (Knott et al., <xref rid="B27" ref-type="bibr">2008</xref>). Mitofusins (MFN1 and MFN2) and optic atrophy 1 (OPA1) are proteins required for controlling mitochondrial fusion, and fission depends mainly on dynamin-related protein 1 (DRP1) activity (Wang et al., <xref rid="B59" ref-type="bibr">2009a</xref>; Friedman et al., <xref rid="B16" ref-type="bibr">2011</xref>; Murley et al., <xref rid="B39" ref-type="bibr">2013</xref>). Analysis of Drp1 expression did not show significant differences comparing AD fibroblasts with control patient's cells (Figures <xref ref-type="fig" rid="F2">2A,B</xref>). Further analysis of MFN1 expression showed a double band at 84kDa and 71kDa in all the samples (Santel et al., <xref rid="B53" ref-type="bibr">2003</xref>) (Figure <xref ref-type="fig" rid="F2">2C</xref>). Interestingly, in control patients, both splicing variants of the MFN1 protein were equally expressed (Figure <xref ref-type="fig" rid="F2">2D</xref>). In contrast, AD patients presented a significant increase in the shorter band (Figure <xref ref-type="fig" rid="F2">2D</xref>). Quantification of OPA1 expression showed a significant reduction in AD fibroblasts respect to the control cells (Figures <xref ref-type="fig" rid="F2">2E,F</xref>). On the other hand, OPA1 is regulated both at the transcriptional and post-transcriptional level (Rugarli and Langer, <xref rid="B52" ref-type="bibr">2012</xref>), and their processing resulted in the accumulation of two long forms (L1 and L2) and three short soluble forms (S3, S4, and S5) (Rugarli and Langer, <xref rid="B52" ref-type="bibr">2012</xref>). We found that AD fibroblasts showed a specific pattern of OPA1 processing compared to control patients (Figure <xref ref-type="fig" rid="F2">2D</xref>), which consisted of a significant decrease in L1, S3, and S4 and a prominent increase in S5 form (Figure <xref ref-type="fig" rid="F2">2G</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Defects in mitochondrial fusion regulation in fibroblasts obtained from AD patients. <bold>(A)</bold> The levels of mitochondrial fission protein DRP1, in AD and control patients were determined by Western blot (see Methods). <bold>(B)</bold> Quantitative analysis of DRP1 relative expression. Data are mean &#x000b1; SE. <bold>(C)</bold> Levels of mitochondrial fusion protein MFN1 are indicating the protein splicing variants (arrows). <bold>(D)</bold> Quantification of the MFN1 splicing products. <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicates differences between groups calculated by Student <italic>t</italic>-test, data are mean &#x000b1; SE. <bold>(E)</bold> Levels of mitochondrial fusion protein OPA1 showing isoforms and proteolytic products of OPA1 (arrows). <bold>(F,G)</bold> Quantification of OPA1 content and isoforms pattern. <sup>*</sup><italic>p</italic> &#x0003c; 0.05, <sup>**</sup><italic>p</italic> &#x0003c; 0.01 indicate differences between groups calculated by Student <italic>t</italic>-test, data are mean &#x000b1; SE.</p></caption><graphic xlink:href="fnins-11-00553-g0002"/></fig></sec><sec><title>Defects in mitochondrial bioenergetics in fibroblasts from AD patients</title><p>We evaluated mitochondrial membrane potential in cultured fibroblasts from control and AD patients using TMRM (Figures <xref ref-type="fig" rid="F3">3A,B</xref>; Brand and Nicholls, <xref rid="B6" ref-type="bibr">2011</xref>; Vargas et al., <xref rid="B57" ref-type="bibr">2014</xref>). No significant changes in mitochondrial potential levels were detected in patients with AD compared to age-matched controls in basal conditions (Figures <xref ref-type="fig" rid="F3">3A,B</xref>). Complementary, we studied ROS levels using DCF (Quintanilla et al., <xref rid="B49" ref-type="bibr">2009</xref>; Figure <xref ref-type="fig" rid="F3">3C</xref>). Fluorescence images showed a significant increase in DCF fluorescence levels in AD fibroblasts compared to control cells (Figure <xref ref-type="fig" rid="F3">3</xref>). Quantitative analysis showed that AD patients showed a significant increase in ROS levels compared to control patients (Figure <xref ref-type="fig" rid="F3">3D</xref>). We also measured the total ATP levels in all patient fibroblasts (Figure <xref ref-type="fig" rid="F3">3E</xref>), finding an interesting decrease in ATP levels (Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref>, ADP2, and ADP3) in AD fibroblasts compared with control cells (NP1-3) (Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref>). However, further analysis of these data indicated no statistical differences between control and AD patients (Figure <xref ref-type="fig" rid="F3">3E</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Fibroblasts of AD patients showed an increase in reactive oxygen species (ROS). <bold>(A)</bold> Representative fluorescent images of TMRM show mitochondrial membrane potential levels in fibroblasts of control and AD patients. Bar = 10 &#x003bc;m. <bold>(B)</bold> The graph represents a quantitate data of mitochondrial potential levels as arbitrary units. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <bold>(C)</bold> Representative fluorescent images of DCF intensity. Bar = 10 &#x003bc;m. <bold>(D)</bold> Graph shows quantitative data of ROS levels in each patient's cell type. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicated differences between groups calculated by Student <italic>t</italic>-test. <bold>(E)</bold> The graph shows total ATP levels (pmol) normalized by &#x003bc;g of protein extracted from control and AD fibroblasts. Data are mean &#x000b1; SE, <italic>n</italic> = 3. <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicate differences between groups calculated by Student <italic>t</italic>-test.</p></caption><graphic xlink:href="fnins-11-00553-g0003"/></fig></sec><sec><title>Cytosolic calcium defects in fibroblasts from AD patients</title><p>It is widely accepted that mitochondria have an important role in calcium regulation in physiological and pathological conditions (De Stefani et al., <xref rid="B14" ref-type="bibr">2016</xref>). To study the relative calcium levels in fibroblasts from control and AD patients, we used Fluo-3AM dye, and the cytosolic calcium levels were determined in a fluorescence microscope (Quintanilla et al., <xref rid="B49" ref-type="bibr">2009</xref>). Figure <xref ref-type="fig" rid="F4">4A</xref> show representative images of relative cytosolic calcium levels in the analyzed fibroblasts, which are showing no significant changes in fluorescence intensity of fibroblasts of AD patients compared to controls (Figure <xref ref-type="fig" rid="F4">4B</xref>). Further, we evaluated the cytosolic calcium changes in response to a calcium overload stimuli induced by thapsigargin (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>). Thapsigargin is a cell permeable compound that inhibits calcium uptake by endoplasmic reticulum and thus results in an increase in the levels of intracellular calcium (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>). We quantified the relative levels of cytosolic calcium after the treatment with 10 &#x003bc;M of thapsigargin for 20 min (Figure <xref ref-type="fig" rid="F4">4C</xref>). We found that controls and AD fibroblasts present an increase in cytosolic calcium 1 min after the thapsigargin stimulus, but interestingly in all AD patients, this increase was significantly higher than control patients (Figure <xref ref-type="fig" rid="F4">4D</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Thapsigargin induces cytosolic calcium handling defects in AD fibroblasts. <bold>(A)</bold> Representative images of Fluo3 intensity showing relative basal cytosolic calcium levels in fibroblasts of control and AD patients. Bar = 10 &#x003bc;m. <bold>(B)</bold> Quantification of relative cytosolic calcium levels as arbitrary units. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <bold>(C)</bold> Representative trends of cytosolic calcium levels over 25 min in AD and control fibroblasts. After 5 min the cells were treated with 10&#x003bc;M of thapsigargin (arrow). Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). (<bold>D)</bold> Relative cytosolic calcium levels 1 min after treatment with thapsigargin (peak of calcium increase). Data are mean &#x000b1; SE. <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicated differences between groups calculated by Student <italic>t</italic>-test.</p></caption><graphic xlink:href="fnins-11-00553-g0004"/></fig><p>To assess if calcium stress compromises mitochondrial dynamics, we evaluate mitochondrial length in fibroblasts exposed to thapsigargin (Figure <xref ref-type="fig" rid="F5">5</xref>). We found that AD fibroblasts presented a reduction in mitochondrial length compared to the untreated condition (Figure <xref ref-type="fig" rid="F5">5A</xref>). Interestingly, when we studied the changes in mitochondrial potential in response to thapsigargin treatment (Figure <xref ref-type="fig" rid="F5">5B</xref>), we observed that AD fibroblasts presented a significant decrease in mitochondrial potential (Figure <xref ref-type="fig" rid="F5">5B</xref>). Finally, to evaluate the contribution of mitochondria in the calcium deregulation observed in AD fibroblasts, we pre-treated cultured fibroblasts with the mitochondrial uncoupler, FCCP, which completely reduces mitochondrial membrane potential (Quintanilla et al., <xref rid="B48" ref-type="bibr">2013</xref>; Figure <xref ref-type="fig" rid="F5">5C</xref>). We found that in this case, both controls and AD patients presented an equal increase in cytosolic calcium after thapsigargin stimulus (Figure <xref ref-type="fig" rid="F5">5C</xref>), but that increase is lower than in control condition (Figure <xref ref-type="fig" rid="F5">5D</xref>). Indeed, AD patients have a significant reduction in cytosolic calcium levels compared to control cells (Figure <xref ref-type="fig" rid="F5">5D</xref>), suggesting the participation of the mitochondria in calcium dysregulation induced by thapsigargin in AD fibroblasts.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Calcium overload induces mitochondrial impairment in AD fibroblasts. <bold>(A)</bold> Determination of mitochondrial length changes after 1 min treatment with thapsigargin. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <bold>(B)</bold> Mitochondrial membrane potential levels determinate with TMRM of each patient after 10 &#x003bc;M thapsigargin treatment. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicate differences before and after thapsigargin treatment calculated by Student <italic>t</italic>-test. <bold>(C)</bold> Fibroblasts were treated with 10 &#x003bc;M FCCP for 30 min before the experiment was performed. Quantification of the intensity of Fluo3 showing cytosolic calcium levels over 25 min. After 5 min of basal fluorescence detection, the cells were treated with 10&#x003bc;M of thapsigargin (arrow). Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <bold>(D)</bold> Quantification of cytosolic calcium levels after 1 min treatment with thapsigargin. Data are mean &#x000b1; SE. <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicated differences with or without FCCP, calculated by Student <italic>t</italic>-test.</p></caption><graphic xlink:href="fnins-11-00553-g0005"/></fig></sec><sec><title>Fibroblasts of young healthy patients present a characteristic pattern of mitochondrial dynamics and bioenergetics</title><p>To complement our previous observations regarding mitochondrial bioenergetics, we evaluate mitochondrial dynamics and bioenergetics in fibroblasts obtained from young healthy individuals (Figure <xref ref-type="fig" rid="F6">6</xref>). Mitochondrial potential levels in young fibroblasts did not present significant differences between young, AD patients and age-matched controls (Figure <xref ref-type="fig" rid="F6">6A</xref>). Interestingly, young fibroblasts showed reduced levels of ROS compared to control cells and AD patients (Figure <xref ref-type="fig" rid="F6">6B</xref>). When we evaluate the cytosolic calcium response in young fibroblasts, we found a cytosolic calcium peak 1 min after the thapsigargin stimulus. This calcium peak is in the same levels of control cells but decreased compares to AD patients (Figure <xref ref-type="fig" rid="F6">6C</xref>). Also, young fibroblasts showed increased ATP levels compared to healthy aged and AD patients (Figure <xref ref-type="fig" rid="F6">6D</xref>).</p><fig id="F6" position="float"><label>Figure 6</label><caption><p>Comparison of mitochondrial bioenergetics profile in young, healthy-aged and AD patient fibroblasts. <bold>(A)</bold> The graph represents the mitochondrial membrane potential levels as arbitrary units. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <bold>(B)</bold> Quantification of total ROS levels in each patient as arbitrary units. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <sup>*</sup>, <sup>**</sup>
<italic>p</italic> &#x0003c; 0.05 indicated differences with between groups calculated by one-way ANOVA test. <bold>(C)</bold> Cytosolic calcium levels after 1 min treatment with thapsigargin. Data are mean &#x000b1; SE. <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicated differences between groups calculated by one-way ANOVA test. <bold>(D)</bold> Total ATP levels (pmol) normalized by &#x003bc;g of protein. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <bold>(E)</bold> Changes in the protein expression levels of DRP1, MFN1, and OPA1 were assessed by Western Blot in cell extracts from young, aged-match healthy and AD fibroblasts. A representative image of actin western blot is show as internal control (see additional data in Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref>). <bold>(F)</bold> Quantitative analysis for DRP1 expression levels. Data are mean &#x000b1; SE. <bold>(G)</bold> Quantitative data indicates splicing products for MFN1 expression. <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicates differences between groups calculated by one-way ANOVA test, data are mean &#x000b1; SE. <bold>(H)</bold> Quantification shows total OPA1 expression. <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicate differences calculated by one-way ANOVA test, data are mean &#x000b1; SE. <bold>(I)</bold> The mitochondrial length was visualized using a MitoGreen. Bar = 10 &#x003bc;m. <bold>(J)</bold> Measurement of mitochondrial length (average) in all cell groups. Data are mean &#x000b1; standard error (SE), <italic>n</italic> = 3 (technical replicates for each subject). <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicate differences between groups calculated by one-way ANOVA test.</p></caption><graphic xlink:href="fnins-11-00553-g0006"/></fig><p>Analysis of mitochondrial dynamics in young fibroblast showed no differences in DRP1 expression (Figure <xref ref-type="fig" rid="F6">6F</xref>). However, analysis of MFN1 in young fibroblasts revealed that both splice variants of the MFN1 protein were equally expressed as well as in age-matched controls. However, 71 kDa band is decreased in young patients compared to AD patients (Figure <xref ref-type="fig" rid="F6">6G</xref>). Surprisingly, we found a significant reduction in the expression of OPA1 in young fibroblasts respect to the old control patients (Figure <xref ref-type="fig" rid="F6">6H</xref>). Finally, we measured mitochondrial length using MitoGreen (Figure <xref ref-type="fig" rid="F6">6I</xref>), and young fibroblasts presented a reduction of 15% in the average mitochondrial length compared to control patients with no differences when we compared to AD patient's cells (Figure <xref ref-type="fig" rid="F6">6J</xref>).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this work, we evaluated changes in mitochondrial bioenergetics and morphology to identify possible differences in mitochondrial function of fibroblasts from sporadic AD and match-aged healthy patients. Evaluation of mitochondrial bioenergetics showed that AD patients fibroblasts presented higher levels of ROS (Figure <xref ref-type="fig" rid="F3">3D</xref>) and with no differences in the basal levels of mitochondrial membrane potential (Figure <xref ref-type="fig" rid="F3">3A</xref>). These data are in agreement with other groups that had shown that AD fibroblasts presented higher levels of basal ROS compared to non-AD patients (Gibson et al., <xref rid="B17" ref-type="bibr">1996</xref>; Naderi et al., <xref rid="B41" ref-type="bibr">2006</xref>; Murphy and Steenbergen, <xref rid="B40" ref-type="bibr">2011</xref>). Also, further analysis of total ATP levels for groups (Control vs. AD group) did not show differences between control and AD patients (Figure <xref ref-type="fig" rid="F3">3E</xref>). However, the analysis of each patient (Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref>) indicated that mild-to-moderate and severe AD patients had decreased levels of ATP compared to age-matched healthy patients and preclinical AD patient, suggesting that the compromised bioenergetics state in AD fibroblasts could be related to the progression of the disease.</p><p>On the other hand, studies in AD cell models have been shown that mitochondrial potential is only affected under stressor conditions such as calcium or amyloid beta peptide (Quintanilla et al., <xref rid="B47" ref-type="bibr">2012</xref>; Vargas et al., <xref rid="B57" ref-type="bibr">2014</xref>). In that context, we found that in all analyzed patients showed equal levels of basal calcium (Figures <xref ref-type="fig" rid="F4">4A,B</xref>), and after treatment with thapsigargin produced a significant increase in relative calcium levels in AD patients respect to control cells (Figure <xref ref-type="fig" rid="F4">4</xref>). Also, thapsigargin treatment induced a further decrease in mitochondrial length and a significant reduction in mitochondrial potential in AD patients (Figures <xref ref-type="fig" rid="F5">5A,B</xref>), indicating a reduced capacity of the mitochondria to respond to calcium stress. In fact, treatment with the mitochondrial uncoupler, FCCP completely reduced the enhanced calcium increase in AD fibroblasts (Figures <xref ref-type="fig" rid="F5">5C,D</xref>), suggesting that the incapacity of calcium buffering is related to mitochondrial impairment in AD patients. Interestingly, studies in young healthy patients revealed that young fibroblasts presented higher ATP levels, less ROS production, and intact calcium buffering capacity compared to healthy elderly patients (Figure <xref ref-type="fig" rid="F6">6</xref>). These findings suggest that in these fibroblasts the aging process could be associated with a reduction of mitochondrial bioenergetics similar to what is observed in mice models (Brunk and Terman, <xref rid="B7" ref-type="bibr">2002</xref>; Lores-Arnaiz et al., <xref rid="B31" ref-type="bibr">2016</xref>; Wyss-Coray, <xref rid="B61" ref-type="bibr">2016</xref>).</p><p>Studies in AD brain samples have shown fragmented mitochondria (Wang et al., <xref rid="B60" ref-type="bibr">2009b</xref>), a decrease in mitochondrial density in synaptic structures (Du et al., <xref rid="B15" ref-type="bibr">2010</xref>), and an altered expression of fission and fusion proteins which could explain the mitochondrial fragmentation (Wang et al., <xref rid="B59" ref-type="bibr">2009a</xref>). Here we showed that fibroblasts of sporadic AD patients presented a significant decrease in mitochondrial length and an increase in the percentage of shorter mitochondria respect to the control patients (Figure <xref ref-type="fig" rid="F1">1</xref>). However, we did not detect differences in the levels of the fission protein DRP1 (Figure <xref ref-type="fig" rid="F2">2</xref>). These results are opposite to those described previously that shows that levels of DRP1 were decreased in sporadic AD fibroblasts and that was possibly related to an increase in elongated mitochondria accumulated in perinuclear areas of the cells (Wang et al., <xref rid="B58" ref-type="bibr">2008</xref>). However, our results are in agreement with findings presented in AD mice models and cortical AD samples that showed mitochondrial fragmentation (Wang et al., <xref rid="B58" ref-type="bibr">2008</xref>; Cai and Tammineni, <xref rid="B9" ref-type="bibr">2016</xref>), accompanied with an increase in DRP1 (Manczak et al., <xref rid="B32" ref-type="bibr">2011</xref>) and a decrease in total OPA1 levels (Manczak et al., <xref rid="B32" ref-type="bibr">2011</xref>).</p><p>Moreover, our results strongly suggest that AD fibroblasts present a specific deregulation of mitochondrial fusion proteins through the reduction of OPA1 and MFN1 expression (Figure <xref ref-type="fig" rid="F2">2</xref>). In AD fibroblasts the expression of the 84 kDa isoform of MFN1 is decreased and the 71 kDa isoform is significantly increased (Figure <xref ref-type="fig" rid="F2">2</xref>). Interestingly, it was described that cortical samples of AD patients showed a reduction in the 84 kDa isoform which is related to the severity of the disease (Manczak et al., <xref rid="B32" ref-type="bibr">2011</xref>), but the 71kDa isoform is not present in all the patient's brains (Manczak et al., <xref rid="B32" ref-type="bibr">2011</xref>). Complementary studies showed that the expression of a MFN1-splice variant was specifically upregulated in tumorigenic cells (Chung et al., <xref rid="B11" ref-type="bibr">2001</xref>), suggesting that this different pattern could be related to a disease status (Chung et al., <xref rid="B11" ref-type="bibr">2001</xref>). On the other hand, AD fibroblasts presented a decrease in the expression of total OPA1 and a specific pattern of proteolytic processing, consisting of a decrease in L1, L2, S3, and S4 and an increase in S5 forms (Figure <xref ref-type="fig" rid="F2">2</xref>). Interestingly, it was described that mitochondrial stress affects the distribution of OPA1 and trigger the complete conversion of L-OPA1 into S-OPA1, leading to a stimulation of mitochondrial fission (Anand et al., <xref rid="B3" ref-type="bibr">2014</xref>). Indeed, this specific increase of the S5 form was described as a result of OPA1 processing induced by H<sub>2</sub>O<sub>2</sub> (Anand et al., <xref rid="B3" ref-type="bibr">2014</xref>). These are a novel an interesting findings that suggest that mitochondrial fragmentation in AD fibroblasts could be mediated by an increase in MFN1 71kDa isoform and the irregular processing of OPA1.</p><p>According to recent publications, the use of skin-derived cells to investigate neurodegenerative diseases with the aim of identifying early biomarkers had to attract increased interest (Clos et al., <xref rid="B12" ref-type="bibr">2012</xref>; Ambrosi et al., <xref rid="B2" ref-type="bibr">2014</xref>; Khan and Alkon, <xref rid="B26" ref-type="bibr">2015</xref>). Indeed, several groups have used use fibroblasts as a model to investigate the mechanisms underlying the pathology of these diseases, with the idea of describing how this cell type present the molecular and metabolic defects that are typically reported at central level (Squitieri et al., <xref rid="B54" ref-type="bibr">2010</xref>; Zanellati et al., <xref rid="B63" ref-type="bibr">2015</xref>; Lopez-Fabuel et al., <xref rid="B30" ref-type="bibr">2017</xref>). For example, Squitieri and collaborators had shown that fibroblasts of Huntington disease's (HD) patients provide a potential peripheral marker as skin biopsies presented pathological mitochondrial features that may predict neuronal pathology (Squitieri et al., <xref rid="B54" ref-type="bibr">2010</xref>). In Parkinson disease (PD), several studies had shown that patient's fibroblasts may be a reliable model system to study mitochondrial dysfunction (Mortiboys et al., <xref rid="B38" ref-type="bibr">2008</xref>; Grunewald et al., <xref rid="B19" ref-type="bibr">2010</xref>; Pacelli et al., <xref rid="B42" ref-type="bibr">2011</xref>; Van Der Merwe et al., <xref rid="B55" ref-type="bibr">2014</xref>), as this cell type present alterations in mitochondrial bioenergetics (Zanellati et al., <xref rid="B63" ref-type="bibr">2015</xref>; Lopez-Fabuel et al., <xref rid="B30" ref-type="bibr">2017</xref>), dynamics (Zanellati et al., <xref rid="B63" ref-type="bibr">2015</xref>), and in the expression and assembly of mitochondrial complexes (Lopez-Fabuel et al., <xref rid="B30" ref-type="bibr">2017</xref>). All these alterations were largely confirmed in mitochondria of cultured neurons and forebrain samples of several PD mouse models (Mortiboys et al., <xref rid="B38" ref-type="bibr">2008</xref>; Grunewald et al., <xref rid="B19" ref-type="bibr">2010</xref>; Pacelli et al., <xref rid="B42" ref-type="bibr">2011</xref>; Van Der Merwe et al., <xref rid="B55" ref-type="bibr">2014</xref>; Lopez-Fabuel et al., <xref rid="B30" ref-type="bibr">2017</xref>). In the case of AD, several studies had shown that fibroblasts of patients with FAD presented a reduction in the mitochondrial number and respiratory function (Gray and Quinn, <xref rid="B18" ref-type="bibr">2015</xref>), high levels of ROS (Richardson, <xref rid="B51" ref-type="bibr">1993</xref>; Moreira et al., <xref rid="B36" ref-type="bibr">2007</xref>), reduced levels of antioxidant defenses (Cecchi et al., <xref rid="B10" ref-type="bibr">2002</xref>), and mitochondrial calcium handling defects (Richardson, <xref rid="B51" ref-type="bibr">1993</xref>; Ito et al., <xref rid="B24" ref-type="bibr">1994</xref>); Therefore, our results presented here indicate that fibroblasts obtained from SAD patients could also present the mitochondrial dysfunction features observed in the AD brain.</p><p>Despite the fact that our observations correspond to a limited number of samples, we consider these findings novel and they suggest that mitochondrial function is significantly compromised in AD fibroblasts, presenting identical alterations showed in neuronal cells during AD progression. From our part, further studies will be made increasing the number of samples from control, AD, and MCI patients to corroborate our observations regarding defects in mitochondrial dynamics and bioenergetics.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>AD is a disease commonly associated with cerebral pathology. However, it is accepted that several neurodegenerative diseases where mitochondrial dysfunction is compromised as HD, PD, and ALS, also present also a systemic component that affects peripheral tissues outside the central nervous system. The possibility that skin fibroblasts could reflect these metabolic changes produced in the brain makes this cell type a suitable model to study new biomarkers of AD.</p><p>Despite the small group of samples, we were able to analyze several changes that are characteristic of mitochondrial damage. Interestingly, fibroblasts obtained from patients with sporadic AD show specific defects in mitochondrial dynamics and bioenergetics suggesting a new possible target in search of peripheral biomarkers for AD.</p><p>To our knowledge, the present study represents an interesting characterization of the mitochondrial status of patient's fibroblasts and suggests that the evaluation of mitochondrial function could differentiate normal aging of pathological AD aging. Our work opens the possibility of a new target for the development of AD biomarkers and presents a novel strategy for epidemiological studies in this disease.</p></sec><sec id="s6"><title>Ethics statement</title><p>A total of 7 patients participated in this study after signed an informed consent approved by the Bioethics Committee of the Hospital Cl&#x000ed;nico de la Universidad de Chile. In severe cases of dementia, their caregivers provided the consent. This study as been endorsed by the Bioethics Committee of the Hospital Cl&#x000ed;nico de la Universidad de Chile and validated by the Universidad Aut&#x000f3;noma de Chile.</p></sec><sec id="s7"><title>Author contributions</title><p>MP: Performed research, designed experiments, collected data, analyzed data, wrote paper. DP: Collected data, analyzed data. CO: Collected data, revised paper. MB: Contributed with patients samples, analyzed data, revised paper. RQ: Directed the project, designed experiments, contributed important reagents, analyzed data, and revised paper.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>We thank the patients and their families and health care personnel for participating in the study.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by Fondo de Ciencia y Tecnolog&#x000ed;a (FONDECYT), Chile: Grants 1140968, 1170441 [to RQ]; 1151297 [to MB], and 11130424 [to CO], as well as CONICYT PIA, Anillo ACT1411 [to RQ and CO].</p></fn></fn-group><sec sec-type="supplementary-material" id="s8"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fnins.2017.00553/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fnins.2017.00553/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><label>Figure S1</label><caption><p>Mitochondrial fusion is defective in fibroblasts obtained from AD patients. Figure shows full western blot membranes and all loading controls for mitochondrial dynamic proteins expression. <bold>(A)</bold> The levels of mitochondrial fission protein DRP1, and their internal control actin. <bold>(B)</bold> Levels of mitochondrial fusion protein MFN1, and their internal control actin. <bold>(C)</bold> Levels of mitochondrial fusion protein OPA1, and their internal control actin.</p></caption><media xlink:href="Image1.TIF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><label>Figure S2</label><caption><p>AD fibroblasts present reduced ATP levels compared to age-healthy cells. The graph shows total ATP levels (pmol) normalized by &#x003bc;g of protein extracted from each control and AD fibroblasts. Data are mean &#x000b1; SE, <italic>n</italic> = 3 (technical replicates for each subject). <sup>*</sup><italic>p</italic> &#x0003c; 0.05 indicate differences between groups calculated by one-way ANOVA.</p></caption><media xlink:href="Image2.TIF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>S. P.</given-names></name><name><surname>Rajan</surname><given-names>S.</given-names></name><name><surname>Duffy</surname><given-names>L.</given-names></name><name><surname>Mortiboys</surname><given-names>H.</given-names></name><name><surname>Higginbottom</surname><given-names>A.</given-names></name><name><surname>Grierson</surname><given-names>A. J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis</article-title>. <source>Neurobiol. Aging</source>
<volume>35</volume>, <fpage>1499</fpage>&#x02013;<lpage>1509</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.11.025</pub-id><?supplied-pmid 24439480?><pub-id pub-id-type="pmid">24439480</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosi</surname><given-names>G.</given-names></name><name><surname>Ghezzi</surname><given-names>C.</given-names></name><name><surname>Sepe</surname><given-names>S.</given-names></name><name><surname>Milanese</surname><given-names>C.</given-names></name><name><surname>Payan-Gomez</surname><given-names>C.</given-names></name><name><surname>Bombardieri</surname><given-names>C. R.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1842</volume>, <fpage>1385</fpage>&#x02013;<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2014.05.008</pub-id><?supplied-pmid 24854107?><pub-id pub-id-type="pmid">24854107</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>R.</given-names></name><name><surname>Wai</surname><given-names>T.</given-names></name><name><surname>Baker</surname><given-names>M. J.</given-names></name><name><surname>Kladt</surname><given-names>N.</given-names></name><name><surname>Schauss</surname><given-names>A. C.</given-names></name><name><surname>Rugarli</surname><given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission</article-title>. <source>J. Cell Biol.</source>
<volume>204</volume>, <fpage>919</fpage>&#x02013;<lpage>929</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201308006</pub-id><?supplied-pmid 24616225?><pub-id pub-id-type="pmid">24616225</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barage</surname><given-names>S. H.</given-names></name><name><surname>Sonawane</surname><given-names>K. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease</article-title>. <source>Neuropeptides</source>. <volume>52</volume>, <fpage>1</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.npep.2015.06.008</pub-id><?supplied-pmid 26149638?><pub-id pub-id-type="pmid">26149638</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolome</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>H. C.</given-names></name><name><surname>Burchell</surname><given-names>V. S.</given-names></name><name><surname>Preza</surname><given-names>E.</given-names></name><name><surname>Wray</surname><given-names>S.</given-names></name><name><surname>Mahoney</surname><given-names>C. J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels</article-title>. <source>Neuron</source>
<volume>78</volume>, <fpage>57</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.02.028</pub-id><?supplied-pmid 23498975?><pub-id pub-id-type="pmid">23498975</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>M. D.</given-names></name><name><surname>Nicholls</surname><given-names>D. G.</given-names></name></person-group> (<year>2011</year>). <article-title>Assesing mitochondrial dysfunction in cells</article-title>. <source>Biochem. J.</source>
<volume>435</volume>, <fpage>297</fpage>&#x02013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20110162</pub-id><?supplied-pmid 21726199?><pub-id pub-id-type="pmid">21726199</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunk</surname><given-names>U. T.</given-names></name><name><surname>Terman</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as result of imperfect autophagocytosis</article-title>. <source>Eur. J. Biochem.</source>
<volume>269</volume>, <fpage>1996</fpage>&#x02013;<lpage>2002</lpage>. <pub-id pub-id-type="doi">10.1046/j.1432-1033.2002.02869.x</pub-id><?supplied-pmid 11985575?><pub-id pub-id-type="pmid">11985575</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas-Opazo</surname><given-names>F. A.</given-names></name><name><surname>Vergara-Pulgar</surname><given-names>K.</given-names></name><name><surname>Perez</surname><given-names>M. J.</given-names></name><name><surname>Jara</surname><given-names>C.</given-names></name><name><surname>Osorio-Fuentealba</surname><given-names>C.</given-names></name><name><surname>Quintanilla</surname><given-names>R. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer's disease</article-title>. <source>Oxid. Med. Cell. Longev.</source>
<volume>2015</volume>:<fpage>509654</fpage>. <pub-id pub-id-type="doi">10.1155/2015/509654</pub-id><?supplied-pmid 26221414?><pub-id pub-id-type="pmid">26221414</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q.</given-names></name><name><surname>Tammineni</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Alterations in mitochondrial quality control in Alzheimer's disease</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>10</volume>:<fpage>24</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2016.00024</pub-id><?supplied-pmid 26903809?><pub-id pub-id-type="pmid">26903809</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cecchi</surname><given-names>C.</given-names></name><name><surname>Fiorillo</surname><given-names>C.</given-names></name><name><surname>Sorbi</surname><given-names>S.</given-names></name><name><surname>Latorraca</surname><given-names>S.</given-names></name><name><surname>Nacmias</surname><given-names>B.</given-names></name><name><surname>Bagnoli</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>33</volume>, <fpage>1372</fpage>&#x02013;<lpage>1379</lpage>. <pub-id pub-id-type="doi">10.1016/S0891-5849(02)01049-3</pub-id><?supplied-pmid 12419469?><pub-id pub-id-type="pmid">12419469</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>J. G.</given-names></name><name><surname>Yeh</surname><given-names>K. T.</given-names></name><name><surname>Wu</surname><given-names>S. L.</given-names></name><name><surname>Hsu</surname><given-names>N. Y.</given-names></name><name><surname>Chen</surname><given-names>G. W.</given-names></name><name><surname>Yeh</surname><given-names>Y. W.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Novel transmembrane GTPase of non-small cell lung cancer identified by mRNA differential display</article-title>. <source>Cancer Res.</source>
<volume>61</volume>, <fpage>8873</fpage>&#x02013;<lpage>8879</lpage>. <?supplied-pmid 11751411?><pub-id pub-id-type="pmid">11751411</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clos</surname><given-names>A. L.</given-names></name><name><surname>Kayed</surname><given-names>R.</given-names></name><name><surname>Lasagna-Reeves</surname><given-names>C. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis</article-title>. <source>Front. Neurol.</source>
<volume>3</volume>:<fpage>5</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2012.00005</pub-id><?supplied-pmid 22319507?><pub-id pub-id-type="pmid">22319507</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>O.</given-names></name><name><surname>Hallett</surname><given-names>P.</given-names></name><name><surname>Isacson</surname><given-names>O.</given-names></name></person-group> (<year>2012</year>). <article-title>Using stem cells and iPS cells to discover new treatments for Parkinson's disease</article-title>. <source>Parkinsonism Relat. Disord.</source>
<volume>18</volume>(<issue>Suppl. 1</issue>), <fpage>S14</fpage>&#x02013;<lpage>S16</lpage>. <pub-id pub-id-type="doi">10.1016/S1353-8020(11)70007-4</pub-id><?supplied-pmid 22166414?><pub-id pub-id-type="pmid">22166414</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Stefani</surname><given-names>D.</given-names></name><name><surname>Rizzuto</surname><given-names>R.</given-names></name><name><surname>Pozzan</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Enjoy the trip: calcium in mitochondria back and forth</article-title>. <source>Annu. Rev. Biochem.</source>
<volume>85</volume>, <fpage>161</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biochem-060614-034216</pub-id><?supplied-pmid 27145841?><pub-id pub-id-type="pmid">27145841</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Sosunov</surname><given-names>A. A.</given-names></name><name><surname>McKhann</surname><given-names>G. M.</given-names></name><name><surname>Yan</surname><given-names>S. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>107</volume>, <fpage>18670</fpage>&#x02013;<lpage>18675</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1006586107</pub-id><?supplied-pmid 20937894?><pub-id pub-id-type="pmid">20937894</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J. R.</given-names></name><name><surname>Lackner</surname><given-names>L. L.</given-names></name><name><surname>West</surname><given-names>M.</given-names></name><name><surname>Dibenedetto</surname><given-names>J. R.</given-names></name><name><surname>Nunnari</surname><given-names>J.</given-names></name><name><surname>Voeltz</surname><given-names>G. K.</given-names></name></person-group> (<year>2011</year>). <article-title>ER tubules mark sites of mitochondrial division</article-title>. <source>Science</source>
<volume>334</volume>, <fpage>358</fpage>&#x02013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1126/science.1207385</pub-id><?supplied-pmid 21885730?><pub-id pub-id-type="pmid">21885730</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>G.</given-names></name><name><surname>Martins</surname><given-names>R.</given-names></name><name><surname>Blass</surname><given-names>J.</given-names></name><name><surname>Gandy</surname><given-names>S.</given-names></name></person-group> (<year>1996</year>). <article-title>Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients</article-title>. <source>Life Sci.</source>
<volume>59</volume>, <fpage>477</fpage>&#x02013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(96)00327-X</pub-id><?supplied-pmid 8761336?><pub-id pub-id-type="pmid">8761336</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>N. E.</given-names></name><name><surname>Quinn</surname><given-names>J. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Alterations in mitochondrial number and function in Alzheimer's disease fibroblasts</article-title>. <source>Metab. Brain Dis.</source>
<volume>30</volume>, <fpage>1275</fpage>&#x02013;<lpage>1278</lpage>. <pub-id pub-id-type="doi">10.1007/s11011-015-9667-z</pub-id><?supplied-pmid 25862550?><pub-id pub-id-type="pmid">25862550</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname><given-names>A.</given-names></name><name><surname>Voges</surname><given-names>L.</given-names></name><name><surname>Rakovic</surname><given-names>A.</given-names></name><name><surname>Kasten</surname><given-names>M.</given-names></name><name><surname>Vandebona</surname><given-names>H.</given-names></name><name><surname>Hemmelmann</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts</article-title>. <source>PLoS ONE</source>
<volume>5</volume>:<fpage>e12962</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0012962</pub-id><?supplied-pmid 20885945?><pub-id pub-id-type="pmid">20885945</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirtz</surname><given-names>D.</given-names></name><name><surname>Thurman</surname><given-names>D. J.</given-names></name><name><surname>Gwinn-Hardy</surname><given-names>K.</given-names></name><name><surname>Mohamed</surname><given-names>M.</given-names></name><name><surname>Chaudhuri</surname><given-names>A. R.</given-names></name><name><surname>Zalutsky</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>How common are the &#x0201c;common&#x0201d; neurologic disorders?</article-title>
<source>Neurology</source>
<volume>68</volume>, <fpage>326</fpage>&#x02013;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000252807.38124.a3</pub-id><?supplied-pmid 17261678?><pub-id pub-id-type="pmid">17261678</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hom</surname><given-names>J.</given-names></name><name><surname>Quintanilla</surname><given-names>R. A.</given-names></name><name><surname>Hoffman</surname><given-names>D.</given-names></name><name><surname>Karen</surname><given-names>M. B.</given-names></name><name><surname>Molkentin</surname><given-names>J. D.</given-names></name><name><surname>Sheu</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation</article-title>. <source>Dev. Cell</source>. <volume>21</volume>, <fpage>469</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2011.08.008</pub-id><?supplied-pmid 21920313?><pub-id pub-id-type="pmid">21920313</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>C. C.</given-names></name><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>J. T.</given-names></name></person-group> (<year>2016</year>). <article-title>A mitocentric view of Alzheimer's disease</article-title>. <source>Mol. Neurobiol</source>. <volume>54</volume>, <fpage>6046</fpage>&#x02013;<lpage>6060</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-0117-7</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Mucke</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>Alzheimer mechanisms and therapeutic strategies</article-title>. <source>Cell</source>
<volume>148</volume>, <fpage>1204</fpage>&#x02013;<lpage>1222</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.02.040</pub-id><?supplied-pmid 22424230?><pub-id pub-id-type="pmid">22424230</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>E.</given-names></name><name><surname>Oka</surname><given-names>K.</given-names></name><name><surname>Etcheberrigaray</surname><given-names>R.</given-names></name><name><surname>Nelson</surname><given-names>T. J.</given-names></name><name><surname>Mcphie</surname><given-names>D. L.</given-names></name><name><surname>Tofel-Grehl</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>1994</year>). <article-title>Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>91</volume>, <fpage>534</fpage>&#x02013;<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.91.2.534</pub-id><?supplied-pmid 8290560?><pub-id pub-id-type="pmid">8290560</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalman</surname><given-names>S.</given-names></name><name><surname>Garbett</surname><given-names>K. A.</given-names></name><name><surname>Janka</surname><given-names>Z.</given-names></name><name><surname>Mirnics</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Human dermal fibroblasts in psychiatry research</article-title>. <source>Neuroscience</source>
<volume>320</volume>, <fpage>105</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.01.067</pub-id><?supplied-pmid 26855193?><pub-id pub-id-type="pmid">26855193</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>T. K.</given-names></name><name><surname>Alkon</surname><given-names>D. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Peripheral biomarkers of Alzheimer's disease</article-title>. <source>J. Alzheimers. Dis.</source>
<volume>44</volume>, <fpage>729</fpage>&#x02013;<lpage>744</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-142262</pub-id>. <?supplied-pmid 25374110?><pub-id pub-id-type="pmid">25374110</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>A. B.</given-names></name><name><surname>Perkins</surname><given-names>G.</given-names></name><name><surname>Schwarzenbacher</surname><given-names>R.</given-names></name><name><surname>Bossy-Wetzel</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Mitochondrial fragmentation in neurodegeneration</article-title>. <source>Nat. Rev. Neurosci.</source>
<volume>9</volume>, <fpage>505</fpage>&#x02013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2417</pub-id><?supplied-pmid 18568013?><pub-id pub-id-type="pmid">18568013</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanfranco</surname><given-names>R. G.</given-names></name><name><surname>Manriquez-Navarro</surname><given-names>P.</given-names></name><name><surname>Avello</surname><given-names>L. G.</given-names></name><name><surname>Canales-Johnson</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>[Early evaluation of Alzheimer's disease: biomarkers and neuropsychological tests]</article-title>. <source>Rev. Med. Chil.</source>
<volume>140</volume>, <fpage>1191</fpage>&#x02013;<lpage>1200</lpage>. <pub-id pub-id-type="doi">10.4067/S0034-98872012000900014</pub-id><?supplied-pmid 23354643?><pub-id pub-id-type="pmid">23354643</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Erauskin</surname><given-names>J.</given-names></name><name><surname>Galino</surname><given-names>J.</given-names></name><name><surname>Bianchi</surname><given-names>P.</given-names></name><name><surname>Fourcade</surname><given-names>S.</given-names></name><name><surname>Andreu</surname><given-names>A. L.</given-names></name><name><surname>Ferrer</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy</article-title>. <source>Brain</source>
<volume>135</volume>, <fpage>3584</fpage>&#x02013;<lpage>3598</lpage>. <pub-id pub-id-type="doi">10.1093/brain/aws292</pub-id><?supplied-pmid 23250880?><pub-id pub-id-type="pmid">23250880</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Fabuel</surname><given-names>I.</given-names></name><name><surname>Martin-Martin</surname><given-names>L.</given-names></name><name><surname>Resch-Beusher</surname><given-names>M.</given-names></name><name><surname>Azkona</surname><given-names>G.</given-names></name><name><surname>Sanchez-Pernaute</surname><given-names>R.</given-names></name><name><surname>Bolanos</surname><given-names>J. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Mitochondrial respiratory chain disorganization in Parkinson's disease-relevant PINK1 and DJ1 mutants</article-title>. <source>Neurochem. Int</source>. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.neuint.2017.03.023</pub-id><?supplied-pmid 28408307?><pub-id pub-id-type="pmid">28408307</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lores-Arnaiz</surname><given-names>S.</given-names></name><name><surname>Lombardi</surname><given-names>P.</given-names></name><name><surname>Karadayian</surname><given-names>A. G.</given-names></name><name><surname>Orgambide</surname><given-names>F.</given-names></name><name><surname>Cicerchia</surname><given-names>D.</given-names></name><name><surname>Bustamante</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Brain cortex mitochondrial bioenergetics in synaptosomes and non-synaptic mitochondria during aging</article-title>. <source>Neurochem. Res.</source>
<volume>41</volume>, <fpage>353</fpage>&#x02013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-015-1817-5</pub-id><?supplied-pmid 26818758?><pub-id pub-id-type="pmid">26818758</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manczak</surname><given-names>M.</given-names></name><name><surname>Calkins</surname><given-names>M. J.</given-names></name><name><surname>Reddy</surname><given-names>P. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage</article-title>. <source>Hum. Mol. Genet.</source>
<volume>20</volume>, <fpage>2495</fpage>&#x02013;<lpage>2509</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddr139</pub-id><?supplied-pmid 21459773?><pub-id pub-id-type="pmid">21459773</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchina</surname><given-names>E.</given-names></name><name><surname>Misasi</surname><given-names>S.</given-names></name><name><surname>Bozzato</surname><given-names>A.</given-names></name><name><surname>Ferraboli</surname><given-names>S.</given-names></name><name><surname>Agosti</surname><given-names>C.</given-names></name><name><surname>Rozzini</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Gene expression profile in fibroblasts of Huntington's disease patients and controls</article-title>. <source>J. Neurol. Sci.</source>
<volume>337</volume>, <fpage>42</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2013.11.014</pub-id><?supplied-pmid 24296361?><pub-id pub-id-type="pmid">24296361</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mckhann</surname><given-names>G.</given-names></name><name><surname>Drachman</surname><given-names>D.</given-names></name><name><surname>Folstein</surname><given-names>M.</given-names></name><name><surname>Katzman</surname><given-names>R.</given-names></name><name><surname>Price</surname><given-names>D.</given-names></name><name><surname>Stadlan</surname><given-names>E. M.</given-names></name></person-group> (<year>1984</year>). <article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease</article-title>. <source>Neurology</source>
<volume>34</volume>, <fpage>939</fpage>&#x02013;<lpage>944</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.34.7.939</pub-id><?supplied-pmid 6610841?><pub-id pub-id-type="pmid">6610841</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcneill</surname><given-names>A.</given-names></name><name><surname>Healy</surname><given-names>D. G.</given-names></name><name><surname>Schapira</surname><given-names>A. H.</given-names></name><name><surname>Taanman</surname><given-names>J. W.</given-names></name></person-group> (<year>2013</year>). <article-title>Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations</article-title>. <source>Mol. Genet. Metab.</source>
<volume>109</volume>, <fpage>402</fpage>&#x02013;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2013.06.002</pub-id><?supplied-pmid 23803291?><pub-id pub-id-type="pmid">23803291</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>P. I.</given-names></name><name><surname>Harris</surname><given-names>P. L.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Santos</surname><given-names>M. S.</given-names></name><name><surname>Oliveira</surname><given-names>C. R.</given-names></name><name><surname>Smith</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts</article-title>. <source>J. Alzheimers. Dis.</source>
<volume>12</volume>, <fpage>195</fpage>&#x02013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2007-12210</pub-id><?supplied-pmid 17917164?><pub-id pub-id-type="pmid">17917164</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>J. C.</given-names></name></person-group> (<year>1993</year>). <article-title>The Clinical Dementia Rating (CDR): current version and scoring rules</article-title>. <source>Neurology</source>
<volume>43</volume>, <fpage>2412</fpage>&#x02013;<lpage>2414</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.43.11.2412-a</pub-id><?supplied-pmid 8232972?><pub-id pub-id-type="pmid">8232972</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortiboys</surname><given-names>H.</given-names></name><name><surname>Thomas</surname><given-names>K. J.</given-names></name><name><surname>Koopman</surname><given-names>W. J.</given-names></name><name><surname>Klaffke</surname><given-names>S.</given-names></name><name><surname>Abou-Sleiman</surname><given-names>P.</given-names></name><name><surname>Olpin</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts</article-title>. <source>Ann. Neurol.</source>
<volume>64</volume>, <fpage>555</fpage>&#x02013;<lpage>565</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21492</pub-id><?supplied-pmid 19067348?><pub-id pub-id-type="pmid">19067348</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murley</surname><given-names>A.</given-names></name><name><surname>Lackner</surname><given-names>L. L.</given-names></name><name><surname>Osman</surname><given-names>C.</given-names></name><name><surname>West</surname><given-names>M.</given-names></name><name><surname>Voeltz</surname><given-names>G. K.</given-names></name><name><surname>Walter</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>ER-associated mitochondrial division links the distiobution of mitochondria and mitochondrial DNA in yeast</article-title>. <source>Elife</source>
<volume>2</volume>:<fpage>e00422</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.00422</pub-id><?supplied-pmid 23682313?><pub-id pub-id-type="pmid">23682313</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>E.</given-names></name><name><surname>Steenbergen</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>What makes the mitochondria a killer? Can we condition them to be less destructive?</article-title>
<source>Biochim. Biophys. Acta</source>
<volume>1813</volume>, <fpage>1302</fpage>&#x02013;<lpage>1308</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2010.09.003</pub-id><?supplied-pmid 20837069?><pub-id pub-id-type="pmid">20837069</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naderi</surname><given-names>J.</given-names></name><name><surname>Lopez</surname><given-names>C.</given-names></name><name><surname>Pandey</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Chronically increased oxidative stress in fibroblasts from Alzheimer's disease patients causes early senescence and renders resistance to apoptosis by oxidative stress</article-title>. <source>Mech. Ageing Dev.</source>
<volume>127</volume>, <fpage>25</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.mad.2005.08.006</pub-id><?supplied-pmid 16188294?><pub-id pub-id-type="pmid">16188294</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacelli</surname><given-names>C.</given-names></name><name><surname>De Rasmo</surname><given-names>D.</given-names></name><name><surname>Signorile</surname><given-names>A.</given-names></name><name><surname>Grattagliano</surname><given-names>I.</given-names></name><name><surname>Di Tullio</surname><given-names>G.</given-names></name><name><surname>D'orazio</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Mitochondrial defect and PGC-1&#x003b1; dysfunction in parkin-associated familial Parkinson's disease</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1812</volume>, <fpage>1041</fpage>&#x02013;<lpage>1053</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2010.12.022</pub-id><?supplied-pmid 21215313?><pub-id pub-id-type="pmid">21215313</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papkovskaia</surname><given-names>T. D.</given-names></name><name><surname>Chau</surname><given-names>K. Y.</given-names></name><name><surname>Inesta-Vaquera</surname><given-names>F.</given-names></name><name><surname>Papkovsky</surname><given-names>D. B.</given-names></name><name><surname>Healy</surname><given-names>D. G.</given-names></name><name><surname>Nishio</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization</article-title>. <source>Hum. Mol. Genet.</source>
<volume>21</volume>, <fpage>4201</fpage>&#x02013;<lpage>4213</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/dds244</pub-id><?supplied-pmid 22736029?><pub-id pub-id-type="pmid">22736029</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>M. J.</given-names></name><name><surname>Jara</surname><given-names>C.</given-names></name><name><surname>Mu-oz-Urrutia</surname><given-names>E.</given-names></name><name><surname>Quintanilla</surname><given-names>R. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Chapter 14: New targets for diagnosis and treatment against Alzheimer's disease: the mitochondrial approach</article-title>, in <source>Update on Dementia</source>, ed <person-group person-group-type="editor"><name><surname>Moretti</surname><given-names>D.</given-names></name></person-group> (<publisher-loc>Rijeka</publisher-loc>: <publisher-name>InTech</publisher-name>).</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prause</surname><given-names>J.</given-names></name><name><surname>Goswami</surname><given-names>A.</given-names></name><name><surname>Katona</surname><given-names>I.</given-names></name><name><surname>Roos</surname><given-names>A.</given-names></name><name><surname>Schnizler</surname><given-names>M.</given-names></name><name><surname>Bushuven</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis</article-title>. <source>Hum. Mol. Genet.</source>
<volume>22</volume>, <fpage>1581</fpage>&#x02013;<lpage>1600</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddt008</pub-id><?supplied-pmid 23314020?><pub-id pub-id-type="pmid">23314020</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querfurth</surname><given-names>H. W.</given-names></name><name><surname>LaFerla</surname><given-names>F. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Alzheimer's disease</article-title>. <source>New Engl. J. Med.</source>
<volume>362</volume>, <fpage>329</fpage>&#x02013;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra0909142</pub-id><?supplied-pmid 20107219?><pub-id pub-id-type="pmid">20107219</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintanilla</surname><given-names>R. A.</given-names></name><name><surname>Dolan</surname><given-names>P. J.</given-names></name><name><surname>Jin</surname><given-names>Y. N.</given-names></name><name><surname>Johnson</surname><given-names>G. V.</given-names></name></person-group> (<year>2012</year>). <article-title>Truncated tau and A&#x003b2; cooperatively impair mitochondria in primary neurons</article-title>. <source>Neurobiol. Aging</source>
<volume>33</volume>, <fpage>619.e25</fpage>&#x02013;<lpage>619.e35</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.02.007</pub-id><?supplied-pmid 21450370?><pub-id pub-id-type="pmid">21450370</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintanilla</surname><given-names>R. A.</given-names></name><name><surname>Jin</surname><given-names>Y. N.</given-names></name><name><surname>Von Bernhardi</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>G. V.</given-names></name></person-group> (<year>2013</year>). <article-title>Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease</article-title>. <source>Mol. Neurodegener.</source>
<volume>8</volume>:<fpage>45</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1326-8-45</pub-id><?supplied-pmid 24330821?><pub-id pub-id-type="pmid">24330821</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintanilla</surname><given-names>R. A.</given-names></name><name><surname>Matthews-Roberson</surname><given-names>T. A.</given-names></name><name><surname>Dolan</surname><given-names>P. J.</given-names></name><name><surname>Johnson</surname><given-names>G. V.</given-names></name></person-group> (<year>2009</year>). <article-title>Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease</article-title>. <source>J. Biol. Chem.</source>
<volume>284</volume>, <fpage>18754</fpage>&#x02013;<lpage>18766</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M808908200</pub-id><?supplied-pmid 19389700?><pub-id pub-id-type="pmid">19389700</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakovic</surname><given-names>A.</given-names></name><name><surname>Grunewald</surname><given-names>A.</given-names></name><name><surname>Seibler</surname><given-names>P.</given-names></name><name><surname>Ramirez</surname><given-names>A.</given-names></name><name><surname>Kock</surname><given-names>N.</given-names></name><name><surname>Orolicki</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients</article-title>. <source>Hum. Mol. Genet.</source>
<volume>19</volume>, <fpage>3124</fpage>&#x02013;<lpage>3137</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddq215</pub-id><?supplied-pmid 20508036?><pub-id pub-id-type="pmid">20508036</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>J. S.</given-names></name></person-group> (<year>1993</year>). <article-title>Free radicals in the genesis of Alzheimer's disease</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>695</volume>, <fpage>73</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1993.tb23031.x</pub-id><?supplied-pmid 8239316?><pub-id pub-id-type="pmid">8239316</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rugarli</surname><given-names>E. I.</given-names></name><name><surname>Langer</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitochondrial quality control: a matter of life and death for neurons</article-title>. <source>EMBO J.</source>
<volume>31</volume>, <fpage>1336</fpage>&#x02013;<lpage>1349</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2012.38</pub-id><?supplied-pmid 22354038?><pub-id pub-id-type="pmid">22354038</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santel</surname><given-names>A.</given-names></name><name><surname>Frank</surname><given-names>S.</given-names></name><name><surname>Gaume</surname><given-names>B.</given-names></name><name><surname>Herrler</surname><given-names>M.</given-names></name><name><surname>Youle</surname><given-names>R. J.</given-names></name><name><surname>Fuller</surname><given-names>M. T.</given-names></name></person-group> (<year>2003</year>). <article-title>Mitofusin-1 protein is a generally expressed mediator of mitochondrial fusion in mammalian cells</article-title>. <source>J. Cell Sci.</source>
<volume>116</volume>, <fpage>2763</fpage>&#x02013;<lpage>2774</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.00479</pub-id><?supplied-pmid 12759376?><pub-id pub-id-type="pmid">12759376</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squitieri</surname><given-names>F.</given-names></name><name><surname>Falleni</surname><given-names>A.</given-names></name><name><surname>Cannella</surname><given-names>M.</given-names></name><name><surname>Orobello</surname><given-names>S.</given-names></name><name><surname>Fulceri</surname><given-names>F.</given-names></name><name><surname>Lenzi</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Abnormal morphology of peripheral cell tissues from patients with Huntington disease</article-title>. <source>J. Neural. Transm.</source>
<volume>117</volume>, <fpage>77</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-009-0328-4</pub-id><?supplied-pmid 19834779?><pub-id pub-id-type="pmid">19834779</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Merwe</surname><given-names>C.</given-names></name><name><surname>Loos</surname><given-names>B.</given-names></name><name><surname>Swart</surname><given-names>C.</given-names></name><name><surname>Kinnear</surname><given-names>C.</given-names></name><name><surname>Henning</surname><given-names>F.</given-names></name><name><surname>Van Der Merwe</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Mitochondrial impairment observed in fibroblasts from South African Parkinson's disease patients with parkin mutations</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>447</volume>, <fpage>334</fpage>&#x02013;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.03.151</pub-id><?supplied-pmid 24721425?><pub-id pub-id-type="pmid">24721425</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vangipuram</surname><given-names>M.</given-names></name><name><surname>Ting</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Diaz</surname><given-names>R.</given-names></name><name><surname>Schule</surname><given-names>B.</given-names></name></person-group> (<year>2013</year>). <article-title>Skin punch biopsy explant culture for derivation of primary human fibroblasts</article-title>. <source>J. Vis. Exp.</source> e3779. <pub-id pub-id-type="doi">10.3791/3779</pub-id><?supplied-pmid 23852182?><pub-id pub-id-type="pmid">23852182</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>S.</given-names></name><name><surname>Rangel</surname><given-names>D.</given-names></name><name><surname>Quintanilla</surname><given-names>F.</given-names></name><name><surname>Rodriguez</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Determination of calcium mobility in alkaline-cooked grounded corn in presence of a magnetic field</article-title>. <source>J. Food Sci.</source>
<volume>79</volume>, <fpage>E1343</fpage>&#x02013;<lpage>E1350</lpage>. <pub-id pub-id-type="doi">10.1111/1750-3841.12421</pub-id><?supplied-pmid 24893922?><pub-id pub-id-type="pmid">24893922</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Fujioka</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name></person-group> (<year>2008</year>). <article-title>Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients</article-title>. <source>Am. J. Pathol.</source>
<volume>173</volume>, <fpage>470</fpage>&#x02013;<lpage>482</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2008.071208</pub-id><?supplied-pmid 18599615?><pub-id pub-id-type="pmid">18599615</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>H. G.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name><name><surname>Smith</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2009a</year>). <article-title>Impaired balance of mitochondrial fission and fusion in Alzheimer's disease</article-title>. <source>J. Neurosci.</source>
<volume>29</volume>, <fpage>9090</fpage>&#x02013;<lpage>9103</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1357-09.2009</pub-id><?supplied-pmid 19605646?><pub-id pub-id-type="pmid">19605646</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name><name><surname>Smith</surname><given-names>M. A.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name></person-group> (<year>2009b</year>). <article-title>The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease</article-title>. <source>J. Neurochem.</source>
<volume>109</volume>(<issue>Suppl. 1</issue>), <fpage>153</fpage>&#x02013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.05867.x</pub-id><?supplied-pmid 19393022?><pub-id pub-id-type="pmid">19393022</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Ageing, neurodegeneration and brain rejuvenation</article-title>. <source>Nature</source>
<volume>539</volume>, <fpage>180</fpage>&#x02013;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1038/nature20411</pub-id><?supplied-pmid 27830812?><pub-id pub-id-type="pmid">27830812</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Rettberg</surname><given-names>J. R.</given-names></name><name><surname>Klosinski</surname><given-names>L. P.</given-names></name><name><surname>Cadenas</surname><given-names>E.</given-names></name><name><surname>Diaz-Brinton</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions</article-title>. <source>Mol. Aspects Med.</source>
<volume>32</volume>, <fpage>247</fpage>&#x02013;<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1016/j.mam.2011.10.005</pub-id><?supplied-pmid 22024249?><pub-id pub-id-type="pmid">22024249</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanellati</surname><given-names>M. C.</given-names></name><name><surname>Monti</surname><given-names>V.</given-names></name><name><surname>Barzaghi</surname><given-names>C.</given-names></name><name><surname>Reale</surname><given-names>C.</given-names></name><name><surname>Nardocci</surname><given-names>N.</given-names></name><name><surname>Albanese</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts</article-title>. <source>Front. Genet.</source>
<volume>6</volume>:<fpage>78</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2015.00078</pub-id><?supplied-pmid 25815004?><pub-id pub-id-type="pmid">25815004</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoumakis</surname><given-names>E.</given-names></name><name><surname>Kalantaridou</surname><given-names>S. N.</given-names></name><name><surname>Chrousos</surname><given-names>G. P.</given-names></name></person-group> (<year>2007</year>). <article-title>The &#x0201c;brain-skin connection&#x0201d;: nerve growth factor-dependent pathways for stress-induced skin disorders</article-title>. <source>J. Mol. Med.</source>
<volume>85</volume>, <fpage>1347</fpage>&#x02013;<lpage>1349</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-007-0270-6</pub-id><?supplied-pmid 17938871?><pub-id pub-id-type="pmid">17938871</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>AD</term><def><p>Alzheimer's disease</p></def></def-item><def-item><term>ADP</term><def><p>Alzheimer's disease patient</p></def></def-item><def-item><term>CDR</term><def><p>Clinical Dementia Rating</p></def></def-item><def-item><term>DCF</term><def><p>chloromethyl-2,7-dichlorodihydrofluorescein diacetate</p></def></def-item><def-item><term>DRP1</term><def><p>Dynamin-related protein 1</p></def></def-item><def-item><term>FCCP</term><def><p>Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone</p></def></def-item><def-item><term>GTPase</term><def><p>Guanosine triphosphatase</p></def></def-item><def-item><term>HD</term><def><p>Huntington Disease</p></def></def-item><def-item><term>NP</term><def><p>Normal patient</p></def></def-item><def-item><term>MFN</term><def><p>Mitofusin</p></def></def-item><def-item><term>MMSE</term><def><p>Mini-mental State Examination</p></def></def-item><def-item><term>MoCA</term><def><p>Montreal Cognitive Assessment</p></def></def-item><def-item><term>OPA1</term><def><p>Optic atrophy 1 protein</p></def></def-item><def-item><term>PD</term><def><p>Parkinson Disease</p></def></def-item><def-item><term>ROS</term><def><p>Reactive oxygen species</p></def></def-item><def-item><term>TMRM</term><def><p>Tetramethyl-rhodamine methyl ester.</p></def></def-item></def-list></glossary></back></article>